[
  {
    "ts": null,
    "headline": "Amgen (AMGN) Stock Declines While Market Improves: Some Information for Investors",
    "summary": "In the closing of the recent trading day, Amgen (AMGN) stood at $320.71, denoting a -2.12% move from the preceding trading day.",
    "url": "https://finnhub.io/api/news?id=ed2725b4ea72d05f34eab4327f9489c9bcb6a4d7b202b20297d1e54dbc85b7ba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767654003,
      "headline": "Amgen (AMGN) Stock Declines While Market Improves: Some Information for Investors",
      "id": 137997849,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "In the closing of the recent trading day, Amgen (AMGN) stood at $320.71, denoting a -2.12% move from the preceding trading day.",
      "url": "https://finnhub.io/api/news?id=ed2725b4ea72d05f34eab4327f9489c9bcb6a4d7b202b20297d1e54dbc85b7ba"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Surges 600 Points After U.S. Ousts Maduro; Reddit, IPO Stock Test Entries (Live Coverage)",
    "summary": "Stock Market Today: The Dow Jones index rose after the U.S. ousted Venezuelan President Maduro. Nvidia rallied and Reddit tested an entry.",
    "url": "https://finnhub.io/api/news?id=d35af27b53a70980cb4eafc22ca8e5b2542dbc2db3bcd78c31a26246b4f83a04",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767629637,
      "headline": "Stock Market Today: Dow Surges 600 Points After U.S. Ousts Maduro; Reddit, IPO Stock Test Entries (Live Coverage)",
      "id": 137991934,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Stock Market Today: The Dow Jones index rose after the U.S. ousted Venezuelan President Maduro. Nvidia rallied and Reddit tested an entry.",
      "url": "https://finnhub.io/api/news?id=d35af27b53a70980cb4eafc22ca8e5b2542dbc2db3bcd78c31a26246b4f83a04"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Decliners",
    "summary": "Zenas BioPharma (ZBIO) reported Monday that a phase 3 trial of obexelimab in immunoglobulin G4-relat",
    "url": "https://finnhub.io/api/news?id=671e043ac744a269f9778f21b653fd2928b6b44d750abf5f6751bd521a379338",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767639627,
      "headline": "Top Midday Decliners",
      "id": 137997851,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Zenas BioPharma (ZBIO) reported Monday that a phase 3 trial of obexelimab in immunoglobulin G4-relat",
      "url": "https://finnhub.io/api/news?id=671e043ac744a269f9778f21b653fd2928b6b44d750abf5f6751bd521a379338"
    }
  },
  {
    "ts": null,
    "headline": "How New Drug Launches And Patent Risks Are Rewriting The Story For Amgen (AMGN)",
    "summary": "What Changed in the Amgen Story Amgen’s fair value estimate has been adjusted slightly, moving from about US$322.88 per share to roughly US$327.74 per share, with the discount rate and revenue growth assumptions shifting only modestly. This updated view reflects how mixed Street research is being balanced between confidence in Amgen as a core large cap biopharma name and questions around long term earnings visibility as key products approach patent expiry. Stay with this article to see how...",
    "url": "https://finnhub.io/api/news?id=85a8ee445bb4a3ddce59e3af5acde81696b89fe21f9c35f778a5a55dfa4902c3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767636379,
      "headline": "How New Drug Launches And Patent Risks Are Rewriting The Story For Amgen (AMGN)",
      "id": 137993300,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "What Changed in the Amgen Story Amgen’s fair value estimate has been adjusted slightly, moving from about US$322.88 per share to roughly US$327.74 per share, with the discount rate and revenue growth assumptions shifting only modestly. This updated view reflects how mixed Street research is being balanced between confidence in Amgen as a core large cap biopharma name and questions around long term earnings visibility as key products approach patent expiry. Stay with this article to see how...",
      "url": "https://finnhub.io/api/news?id=85a8ee445bb4a3ddce59e3af5acde81696b89fe21f9c35f778a5a55dfa4902c3"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Up 700 Points After U.S. Ousts Maduro; Reddit Does This As Versant Dives (Live Coverage)",
    "summary": "Stock Market Today: The Dow Jones index rose after the U.S. ousted Venezuelan President Maduro. Nvidia rallied and Reddit tested an entry.",
    "url": "https://finnhub.io/api/news?id=f2cfd5f1ef9e0e24a1625f893a99280e6a671de8c8d27937a4179f26f2238a2f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767634531,
      "headline": "Stock Market Today: Dow Up 700 Points After U.S. Ousts Maduro; Reddit Does This As Versant Dives (Live Coverage)",
      "id": 137992835,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Stock Market Today: The Dow Jones index rose after the U.S. ousted Venezuelan President Maduro. Nvidia rallied and Reddit tested an entry.",
      "url": "https://finnhub.io/api/news?id=f2cfd5f1ef9e0e24a1625f893a99280e6a671de8c8d27937a4179f26f2238a2f"
    }
  },
  {
    "ts": null,
    "headline": "Zenas BioPharma, A Top 1% Stock, Quadrupled In 2025. Why It Just Collapsed.",
    "summary": "Zenas BioPharma stock collapsed Monday despite technically succeeding in a Phase 3 study of its treatment for a rare autoimmune disorder.",
    "url": "https://finnhub.io/api/news?id=ed872ae53e9bf9592b760e776ec27f2e665d4aab46a1f3ca2ef4128f1a920a3a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767632444,
      "headline": "Zenas BioPharma, A Top 1% Stock, Quadrupled In 2025. Why It Just Collapsed.",
      "id": 137992463,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Zenas BioPharma stock collapsed Monday despite technically succeeding in a Phase 3 study of its treatment for a rare autoimmune disorder.",
      "url": "https://finnhub.io/api/news?id=ed872ae53e9bf9592b760e776ec27f2e665d4aab46a1f3ca2ef4128f1a920a3a"
    }
  },
  {
    "ts": null,
    "headline": "Beat the Market the Zacks Way: LATAM, General Motors, Amgen in Focus",
    "summary": "LTM, GM and AMGN highlight Zacks' recent stock-picking wins, delivering notable gains across airlines, autos and biotech despite choppy markets.",
    "url": "https://finnhub.io/api/news?id=03f8273e707a01a49f10314cafa82874920f41cabc7bbe0e67137cac2feed51e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767617520,
      "headline": "Beat the Market the Zacks Way: LATAM, General Motors, Amgen in Focus",
      "id": 137991162,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "LTM, GM and AMGN highlight Zacks' recent stock-picking wins, delivering notable gains across airlines, autos and biotech despite choppy markets.",
      "url": "https://finnhub.io/api/news?id=03f8273e707a01a49f10314cafa82874920f41cabc7bbe0e67137cac2feed51e"
    }
  },
  {
    "ts": null,
    "headline": "Zenas shares crash after top drug misses expectations in immune disease study",
    "summary": "While the company’s bispecific medication obexelimab met its objectives in a trial in IgG4-related disease, it didn’t appear to match the effectiveness of a recently approved Amgen drug.",
    "url": "https://finnhub.io/api/news?id=7222cf6ec7c0d4783f124c60911d1fa52786769263f399161865f062cbb7fb81",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767612360,
      "headline": "Zenas shares crash after top drug misses expectations in immune disease study",
      "id": 137992464,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "While the company’s bispecific medication obexelimab met its objectives in a trial in IgG4-related disease, it didn’t appear to match the effectiveness of a recently approved Amgen drug.",
      "url": "https://finnhub.io/api/news?id=7222cf6ec7c0d4783f124c60911d1fa52786769263f399161865f062cbb7fb81"
    }
  },
  {
    "ts": null,
    "headline": "1 S&P 500 Stock with Exciting Potential and 2 We Question",
    "summary": "While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.",
    "url": "https://finnhub.io/api/news?id=73734c3a936ef878052fe54e8c7124b311961e76d03d970d63842ee70b2a6f5e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767587820,
      "headline": "1 S&P 500 Stock with Exciting Potential and 2 We Question",
      "id": 137991219,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.",
      "url": "https://finnhub.io/api/news?id=73734c3a936ef878052fe54e8c7124b311961e76d03d970d63842ee70b2a6f5e"
    }
  },
  {
    "ts": null,
    "headline": "Taking Another Look at Amgen (AMGN)’s Valuation After Its Recent Share Price Pullback",
    "summary": "Amgen (AMGN) has been quietly grinding higher over the past year, and that steady move is catching more investor attention. With revenue and earnings both growing, the stock’s recent pullback looks worth a closer look. See our latest analysis for Amgen. At around $327.64, Amgen’s modest recent share price pullback comes after a strong 90 day share price return of 11.4 percent and a one year total shareholder return of 29.5 percent, which suggests momentum is still broadly constructive. If...",
    "url": "https://finnhub.io/api/news?id=0aa866282127ab6774bf0f0be8e0471f77ee483b3991590d57f9d402b8097deb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767582613,
      "headline": "Taking Another Look at Amgen (AMGN)’s Valuation After Its Recent Share Price Pullback",
      "id": 137986204,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) has been quietly grinding higher over the past year, and that steady move is catching more investor attention. With revenue and earnings both growing, the stock’s recent pullback looks worth a closer look. See our latest analysis for Amgen. At around $327.64, Amgen’s modest recent share price pullback comes after a strong 90 day share price return of 11.4 percent and a one year total shareholder return of 29.5 percent, which suggests momentum is still broadly constructive. If...",
      "url": "https://finnhub.io/api/news?id=0aa866282127ab6774bf0f0be8e0471f77ee483b3991590d57f9d402b8097deb"
    }
  }
]